CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1825-1831

  Li, Tianren ^a   Xue, Hui ^a   Guo, Yi ^a   Guo, Kejun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin dependent kinase inhibitor 3; Ovarian cancer; Prognosis; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 3; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907061763     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3045     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Dundr P: Ovarian carcinoma: current diagnostic principles. Cesk Patol 46: 53-61, 2010 (In Czech).
3. Seidman JD, Ronnett BM and Kurman RJ: Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 16: 499-512, 2002.
4. Seidman JD and Kurman RJ: Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17: 909-925, vii, 2003.
5. Westfall D, Roma AA and Silva EG: High-grade serous carcinoma of the ovary. Ann Diagn Pathol 13: 285-290, 2009.
6. Vang R, Shih Ie M and Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: 267-282, 2009.
7. Tarin D: Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev 31: 21-39, 2012.
8. Patterson KI, Brummer T, O'Brien PM and Daly RJ: Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418: 475-489, 2009.
9. Niculescu MD, Yamamuro Y and Zeisel SH: Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem 89: 1252-1259, 2004.
10. Yeh CT, Lu SC, Chen TC, Peng CY and Liaw YF: Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res 60: 4697-4700, 2000.
11. Yeh CT, Lu SC, Chao CH and Chao ML: Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun 305: 311-314, 2003.
12. Blum R, Nakdimon I, Goldberg L, et al: E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 119: 527-538, 2006.
13. Wu L, Timmers C, Maiti B, et al: The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457-462, 2001.
14. Demetrick DJ, Matsumoto S, Hannon GJ, et al: Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet 69: 190-192, 1995.
15. MacDermed DM, Khodarev NN, Pitroda SP, et al: MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 3: 16, 2010.
16. Xing C, Xie H, Zhou L, et al: Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation. Biochem Biophys Res Commun 420: 29-35, 2012.
17. Taylor KJ, Sims AH, Liang L, et al: Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res 12: R39, 2010.
18. Lai MW, Chen TC, Pang ST and Yeh CT: Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol 30: 871-878, 2012.
19. Wang L, Sun L, Huang J and Jiang M: Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif 44: 291-299, 2011.
20. Felisiak-Golabek A, Dansonka-Mieszkowska A, Rzepecka I, et al: p19 mRNA and protein expression as new prognostic factor in ovarian cancer patients. Cancer Biol Ther 14: 973-981, 2013.
21. No JH, Moon JM, Kim K and Kim YB: Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest 75: 263-267, 2013.
22. Huang L, Wang HY, Li JD, et al: KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis 4: e745, 2013.
23. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF and Henshall SM: Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10: 5168-5177, 2004.
24. Lee SW, Reimer CL, Fang L, Iruela-Arispe ML and Aaronson SA: Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol 20: 1723-1732, 2000.
25. Chinami M, Yano Y, Yang X, et al: Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP). Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2. J Biol Chem 280: 17235-17242, 2005.
26. Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM and Johnson MD: Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res 67: 130-138, 2007.
27. Lee J, Sung CO, Lee EJ, et al: Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS One 7: e34456, 2012.
28. Chen J, Jackson PK, Kirschner MW and Dutta A: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386-388, 1995.
29. Barford D: The mechanism of protein kinase regulation by protein phosphatases. Biochem Soc Trans 29: 385-391, 2001.
30. Johnson LN, De Moliner E, Brown NR, et al: Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther 93: 113-124, 2002.